About this Medicine article
AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer’s disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial) by Aisen, Paul S.; Zhou, Jin; Irizarry, Michael C.; Kramer, Lynn D; Swanson, Chad J.; Dhadda, Shobha; Rabe, Martin; Krause, Stephen; Li, David JianJun; Raman, Rema; Donohue, Michael C.; Sethuraman, Gopalan; Johnson, Keith A.; Sperling, Reisa A. is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Aisen, Paul S.; Zhou, Jin; Irizarry, Michael C.; Kramer, Lynn D; Swanson, Chad J.; Dhadda, Shobha; Rabe, Martin; Krause, Stephen; Li, David JianJun; Raman, Rema; Donohue, Michael C.; Sethuraman, Gopalan; Johnson, Keith A.; Sperling, Reisa A.
- Publisher
- Elsevier Science; Elsevier ; Elsevier BV; Wiley; Research Square (ISSN 1552-5260)
- Published
- 2020
- Field
- Medicine (Health Sciences)